{"id":"latanoprost-0-005-drug","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Increased iris pigmentation (darkening)"},{"rate":"25-35","effect":"Conjunctival hyperemia (redness)"},{"rate":"5-10","effect":"Eyelash growth (hypertrichosis)"},{"rate":"5-10","effect":"Eye irritation or discomfort"},{"rate":"5-10","effect":"Periocular skin darkening"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Latanoprost binds to prostaglandin F receptors in the eye and enhances drainage of fluid through the uveoscleral (unconventional) pathway. This increased aqueous humor outflow leads to a reduction in intraocular pressure, which is the primary pathogenic mechanism in glaucoma and ocular hypertension. The drug is administered as a topical ophthalmic solution.","oneSentence":"Latanoprost is a prostaglandin F (FP) receptor agonist that increases uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:33:52.661Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT07325240","phase":"PHASE4","title":"24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-11-21","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":30},{"nctId":"NCT07354516","phase":"PHASE2, PHASE3","title":"Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"Qlaris Bio, Inc.","startDate":"2026-03-18","conditions":"OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension","enrollment":36},{"nctId":"NCT06819046","phase":"","title":"Improved Efficacy of Selective Laser Trabeculoplasty With the Addition of Rocklatan Post-treatment vs Artificial Tears Post-treatment","status":"COMPLETED","sponsor":"Colorado Ophthalmology Associates PC","startDate":"2025-02-14","conditions":"Glaucoma","enrollment":70},{"nctId":"NCT07465913","phase":"PHASE4","title":"Rocklatan vs Latanoprost Post-DSLT","status":"NOT_YET_RECRUITING","sponsor":"Eye Centers of Southeast Texas","startDate":"2026-05-06","conditions":"Glaucoma","enrollment":36},{"nctId":"NCT04412096","phase":"PHASE4","title":"Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2020-11-23","conditions":"Glaucoma, OHT - Ocular Hypertension","enrollment":59},{"nctId":"NCT07425535","phase":"EARLY_PHASE1","title":"Optic Nerve Head Strain in Non-glaucoma Subjects","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-03","conditions":"Glaucoma","enrollment":30},{"nctId":"NCT07082816","phase":"PHASE3","title":"Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alcon Research","startDate":"2025-09-02","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":489},{"nctId":"NCT07310719","phase":"NA","title":"A Comparative Study of Intraocular Pressure Control Using Selective Laser Trabeculoplasty and Latanoprost as Initial Treatments for Primary Open Angle Glaucoma and Ocular Hypertension in Lagos State University Teaching Hospital","status":"RECRUITING","sponsor":"Lagos State Health Service Commission","startDate":"2025-10-15","conditions":"Primary Open Angle Glaucoma or Ocular Hypertension","enrollment":138},{"nctId":"NCT06441643","phase":"PHASE2","title":"Next Generation Rocklatan","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2024-09-04","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":426},{"nctId":"NCT07209410","phase":"PHASE4","title":"Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma","status":"RECRUITING","sponsor":"Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,","startDate":"2025-11-01","conditions":"Glaucoma","enrollment":35},{"nctId":"NCT06449352","phase":"PHASE4","title":"Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost","status":"COMPLETED","sponsor":"Westlake Eye Specialists","startDate":"2024-06-13","conditions":"Normal Tension Glaucoma","enrollment":100},{"nctId":"NCT04500574","phase":"PHASE1","title":"Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension","status":"TERMINATED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2024-04-03","conditions":"Glaucoma, Ocular Hypertension","enrollment":1},{"nctId":"NCT04630808","phase":"PHASE3","title":"MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","startDate":"2020-11-09","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":696},{"nctId":"NCT07048886","phase":"PHASE4","title":"Rocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery)","status":"NOT_YET_RECRUITING","sponsor":"Center for Sight Las Vegas","startDate":"2025-07-15","conditions":"Primary Open Angle Glaucoma","enrollment":68},{"nctId":"NCT04445519","phase":"PHASE3","title":"Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","startDate":"2020-06-01","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":691},{"nctId":"NCT06964191","phase":"PHASE2","title":"Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"PolyActiva Pty Ltd","startDate":"2025-05-31","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":75},{"nctId":"NCT07016113","phase":"PHASE2","title":"0.005% Latanoprost Gel for Nonsegmental Vitiligo","status":"NOT_YET_RECRUITING","sponsor":"Universitas Padjadjaran","startDate":"2025-07-01","conditions":"Vitiligo - Macular Depigmentation","enrollment":10},{"nctId":"NCT06960629","phase":"","title":"The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)","status":"ENROLLING_BY_INVITATION","sponsor":"University Hospital Dubrava","startDate":"2025-04-01","conditions":"Pseudophakic Bullous Keratopathy, Glaucoma","enrollment":50},{"nctId":"NCT06883123","phase":"PHASE4","title":"Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost","status":"RECRUITING","sponsor":"Prairie Eye Center","startDate":"2025-05-14","conditions":"Open Angle Glaucoma","enrollment":70},{"nctId":"NCT05583474","phase":"PHASE3","title":"OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2022-09-27","conditions":"Open Angle Glaucoma or Ocular Hypertension","enrollment":204},{"nctId":"NCT06666855","phase":"PHASE3","title":"A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China","status":"RECRUITING","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2024-11-28","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":338},{"nctId":"NCT06407973","phase":"PHASE4","title":"A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma","status":"TERMINATED","sponsor":"Sight Sciences, Inc.","startDate":"2024-08-21","conditions":"Primary Open Angle Glaucoma","enrollment":2},{"nctId":"NCT06730516","phase":"EARLY_PHASE1","title":"Optic Nerve Perfusion Following Treatment with Latanoprost Versus Brimionidin Tartrate","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2024-06-24","conditions":"Glaucoma","enrollment":56},{"nctId":"NCT06629129","phase":"PHASE1","title":"Effect of Latanoprost on Optic Nerve Perfusion","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2024-06-24","conditions":"Treatment Outcome","enrollment":46},{"nctId":"NCT01704989","phase":"PHASE4","title":"The Laser in Pseudoexfoliation (LIP) Study","status":"WITHDRAWN","sponsor":"Nova Scotia Health Authority","startDate":"2012-06","conditions":"Glaucoma","enrollment":""},{"nctId":"NCT02801617","phase":"PHASE3","title":"Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2015-09","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":116},{"nctId":"NCT04761705","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"SUSPENDED","sponsor":"JeniVision, Inc.","startDate":"2021-03-10","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":70},{"nctId":"NCT06239324","phase":"PHASE1, PHASE2","title":"Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser","status":"RECRUITING","sponsor":"Egymedicalpedia","startDate":"2024-02-01","conditions":"Alopecia Areata","enrollment":70},{"nctId":"NCT05283395","phase":"PHASE4","title":"Rocklatan® Evaluation","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2022-03-28","conditions":"Glaucoma","enrollment":136},{"nctId":"NCT02981446","phase":"PHASE3","title":"A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2017-01","conditions":"Open Angle Glaucoma or Ocular Hypertension","enrollment":370},{"nctId":"NCT04702789","phase":"PHASE4","title":"Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2021-10-19","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":28},{"nctId":"NCT05495061","phase":"PHASE3","title":"A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2022-08-09","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":325},{"nctId":"NCT04811326","phase":"PHASE4","title":"Latanoprost Plus NB-UVB Versus Each Alone in Non-segmental Vitiligo: Clinical and Laboratory Evaluation","status":"UNKNOWN","sponsor":"Shaimaa Fawzy Abdel-rady Abdel-latif","startDate":"2021-01-13","conditions":"Non-segmental Vitiligo","enrollment":150},{"nctId":"NCT05513924","phase":"PHASE2, PHASE3","title":"Comparative Study Between Topical 5-fluorouracil and Latanoprost in Vitiligo.","status":"COMPLETED","sponsor":"South Valley University","startDate":"2022-03-15","conditions":"Vitiligo","enrollment":40},{"nctId":"NCT03657797","phase":"PHASE2","title":"Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","startDate":"2018-08-01","conditions":"Glaucoma, Open-Angle, Hypertension, Ocular","enrollment":656},{"nctId":"NCT05606796","phase":"PHASE4","title":"Comparison of Preserved and Preservative-free Latanoprost 0.005% in Primary Open Angle Glaucoma and Ocular Hypertensive Patients, at Guinness Eye Centre, Lagos.","status":"UNKNOWN","sponsor":"Uzoma Chinyei Joan","startDate":"2022-12","conditions":"Effect of Drug","enrollment":76},{"nctId":"NCT05165290","phase":"PHASE3","title":"Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure","status":"UNKNOWN","sponsor":"TearClear Corp","startDate":"2021-11-29","conditions":"Elevated Intraocular Pressure","enrollment":300},{"nctId":"NCT04296916","phase":"NA","title":"Effect of Lowering IOP in Glaucoma Suspects With HM","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-04-17","conditions":"Glaucoma, Suspect, High Myopia","enrollment":264},{"nctId":"NCT02585375","phase":"PHASE4","title":"Latanoprost Preserved Versus Unpreserved: Effect on Tear Film Thickness as Measured With OCT","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2015-09-17","conditions":"Glaucoma, Ocular Hypertension","enrollment":70},{"nctId":"NCT03284853","phase":"PHASE3","title":"Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2017-09-05","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":436},{"nctId":"NCT03949244","phase":"PHASE4","title":"Nailfold Capillary Blood Flow With Latanoprost Bunod","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-08-15","conditions":"Glaucoma, Open-Angle","enrollment":47},{"nctId":"NCT00383019","phase":"PHASE3","title":"A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-11-14","conditions":"Glaucoma, Ocular Hypertension","enrollment":300},{"nctId":"NCT03648229","phase":"PHASE4","title":"African Glaucoma Laser Trial","status":"WITHDRAWN","sponsor":"West Virginia University","startDate":"2019-09-01","conditions":"Open-angle Glaucoma","enrollment":""},{"nctId":"NCT04896125","phase":"","title":"Comparison of Different Drugs on Ocular Surface Disease in Glaucoma Patients: a Prospective Randomised Study","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2019-10-02","conditions":"Glaucoma; Ocular Disorders (I.E. Caused by Ocular Disorders)","enrollment":300},{"nctId":"NCT00572455","phase":"PHASE2","title":"Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-12-11","conditions":"Primary Open-Angle Glaucoma, Ocular Hypertension","enrollment":318},{"nctId":"NCT00950690","phase":"","title":"Efficacy and Tolerability of Xalatan in Patients","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-07","conditions":"Glaucoma, Ocular Hypertension","enrollment":1289},{"nctId":"NCT00856622","phase":"PHASE3","title":"A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"1997-08","conditions":"Ocular Hypertension, Glaucoma, Open-angle Glaucoma","enrollment":436},{"nctId":"NCT00800267","phase":"PHASE3","title":"A Study of Glaucoma or Ocular Hypertension in Patients Within the United States","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"1997-07","conditions":"Ocular Hypertension, Glaucoma","enrollment":418},{"nctId":"NCT00230763","phase":"PHASE3","title":"Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-09","conditions":"Glaucoma, Primary Open Angle (POAG), Ocular Hypertension","enrollment":396},{"nctId":"NCT04737928","phase":"NA","title":"Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)","status":"COMPLETED","sponsor":"Santen Pharmaceutical (Taiwan) Co., LTD","startDate":"2018-04-02","conditions":"Glaucoma, Primary Open Angle","enrollment":1},{"nctId":"NCT00716859","phase":"PHASE3","title":"A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-07","conditions":"Glaucoma","enrollment":139},{"nctId":"NCT00638742","phase":"PHASE1","title":"A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-05","conditions":"Glaucoma, Ocular Hypertension","enrollment":47},{"nctId":"NCT00847483","phase":"PHASE4","title":"Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2002-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":375},{"nctId":"NCT00647101","phase":"PHASE4","title":"A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-12","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":600},{"nctId":"NCT00846989","phase":"PHASE1, PHASE2","title":"Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":276},{"nctId":"NCT02466399","phase":"PHASE2","title":"POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma","status":"COMPLETED","sponsor":"Peregrine Ophthalmic","startDate":"2015-07","conditions":"Glaucoma","enrollment":80},{"nctId":"NCT03216902","phase":"PHASE2","title":"A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2017-07-25","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":241},{"nctId":"NCT00595101","phase":"PHASE2","title":"A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2007-12","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":117},{"nctId":"NCT00441883","phase":"PHASE2","title":"Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2007-03","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension, Pigmentary Glaucoma","enrollment":176},{"nctId":"NCT04461249","phase":"","title":"Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2019-06-01","conditions":"Primary Open Angle Glaucoma","enrollment":60},{"nctId":"NCT04234932","phase":"EARLY_PHASE1","title":"Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation","status":"UNKNOWN","sponsor":"University of the Incarnate Word","startDate":"2020-01-06","conditions":"Glaucoma, Open-Angle","enrollment":10},{"nctId":"NCT02017327","phase":"PHASE4","title":"Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2013-12","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":379},{"nctId":"NCT03293992","phase":"PHASE1","title":"A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-10-10","conditions":"Glaucoma, Open-angle, Ocular Hypertension","enrollment":27},{"nctId":"NCT04178863","phase":"PHASE4","title":"CATS Tonometer IOP Reduction Latanoprost Verses Timolol","status":"UNKNOWN","sponsor":"Intuor Technologies, Inc.","startDate":"2018-07-01","conditions":"Glaucoma; Drugs","enrollment":72},{"nctId":"NCT01527682","phase":"PHASE2","title":"Efficacy and Safety of Topically Applied Medical Therapy for the Treatment of Pediatric Glaucoma","status":"COMPLETED","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2009-07","conditions":"Childhood Glaucoma","enrollment":37},{"nctId":"NCT02558400","phase":"PHASE3","title":"Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2015-09-18","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":718},{"nctId":"NCT02057575","phase":"PHASE2","title":"Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2014-01","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":298},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT02674854","phase":"PHASE3","title":"Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2016-02","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":750},{"nctId":"NCT00440011","phase":"PHASE4","title":"Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%","status":"COMPLETED","sponsor":"Allergan","startDate":"2006-08","conditions":"Glaucoma, Ocular Hypertension","enrollment":266},{"nctId":"NCT00539526","phase":"PHASE4","title":"Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-09","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":106},{"nctId":"NCT00735449","phase":"PHASE4","title":"Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-07","conditions":"Glaucoma, Ocular Hypertension","enrollment":204},{"nctId":"NCT01243567","phase":"PHASE4","title":"Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-06-01","conditions":"Glaucoma, Open-Angle","enrollment":81},{"nctId":"NCT02419508","phase":"PHASE4","title":"SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-08-07","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":290},{"nctId":"NCT03611348","phase":"PHASE2, PHASE3","title":"Microneedling and Latanoprost in Acrofacial Vitiligo","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2018-09-01","conditions":"Vitiligo","enrollment":70},{"nctId":"NCT02059278","phase":"PHASE3","title":"Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Nephron Pharmaceuticals Corporation","startDate":"2014-01","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":335},{"nctId":"NCT01223378","phase":"PHASE2","title":"Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2010-12-13","conditions":"Intraocular Pressure","enrollment":413},{"nctId":"NCT00712400","phase":"NA","title":"Effects of Latanoprost on Choroidal Blood Flow Regulation in Human Subjects","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2005-06","conditions":"Ocular Physiology, Intraocular Pressure, Regional Blood Flow","enrollment":24},{"nctId":"NCT01927406","phase":"PHASE4","title":"The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2014-06","conditions":"Thyroid Eye Disease, Ocular Hypertension, Glaucoma","enrollment":""},{"nctId":"NCT02179008","phase":"PHASE2","title":"Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2014-06","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":184},{"nctId":"NCT01868126","phase":"PHASE2","title":"Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2013-05","conditions":"Open-angle Glaucoma or Ocular Hypertension","enrollment":91},{"nctId":"NCT01731002","phase":"PHASE2","title":"Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2012-11","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":224},{"nctId":"NCT02622334","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-12-29","conditions":"Glaucoma","enrollment":45},{"nctId":"NCT02129673","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"ViSci Ltd.","startDate":"2014-05","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":77},{"nctId":"NCT02829996","phase":"PHASE2","title":"Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG","status":"COMPLETED","sponsor":"Inotek Pharmaceuticals Corporation","startDate":"2016-08-19","conditions":"Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)","enrollment":201},{"nctId":"NCT02822742","phase":"PHASE3","title":"A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2016-07-02","conditions":"Primary Open Angle Glaucoma or Ocular Hypertension","enrollment":26},{"nctId":"NCT02623738","phase":"PHASE2, PHASE3","title":"A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-","status":"COMPLETED","sponsor":"Santen Pharmaceutical Co., Ltd.","startDate":"2015-12-06","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":253},{"nctId":"NCT01535768","phase":"PHASE4","title":"Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves","status":"UNKNOWN","sponsor":"Credit Valley EyeCare","startDate":"2012-02","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT02278614","phase":"PHASE3","title":"Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2014-12","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":242},{"nctId":"NCT01315574","phase":"PHASE4","title":"Effects of Anti-Glaucoma Medications on the Ocular Surface","status":"TERMINATED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2011-02","conditions":"Glaucoma","enrollment":14},{"nctId":"NCT01254370","phase":"PHASE2","title":"Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2010-11","conditions":"Glaucoma, Ocular Hypertension, Ocular Surface Disease","enrollment":105},{"nctId":"NCT02083289","phase":"PHASE2","title":"A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)","status":"COMPLETED","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2014-05","conditions":"Ocular Hypertension, Open Angle-glaucoma","enrollment":123},{"nctId":"NCT00705757","phase":"PHASE4","title":"The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye","status":"COMPLETED","sponsor":"Summa Health System","startDate":"2008-03","conditions":"Glaucoma, Application Site Pigmentation Changes","enrollment":89},{"nctId":"NCT02350023","phase":"PHASE4","title":"Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2014-09","conditions":"Alopecia Areata","enrollment":50},{"nctId":"NCT01975714","phase":"PHASE4","title":"Intraocular Pressure and Tolerability Study of Preservative-free Prostaglandins (Bimatoprost and Latanoprost) on Glaucoma and Ocular Hypertension: European, Multicentric, Investigator-led, Single Masked Study","status":"COMPLETED","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2013-10","conditions":"Glaucoma, Ocular Hypertension","enrollment":67},{"nctId":"NCT00941525","phase":"PHASE4","title":"Central Corneal Thickness and 24-hour Fluctuation of Intraocular Pressure","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2009-09","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":174},{"nctId":"NCT01721707","phase":"PHASE3","title":"Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH","status":"WITHDRAWN","sponsor":"Adapt Produtos Oftalmológicos Ltda.","startDate":"2012-12","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":""},{"nctId":"NCT00706927","phase":"NA","title":"Effect of Xalacom® (Latanoprost/Timolol) and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2006-01","conditions":"Retina, Ocular Physiology","enrollment":16},{"nctId":"NCT01369771","phase":"PHASE4","title":"The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma","status":"COMPLETED","sponsor":"FinnMedi Oy","startDate":"2010-08","conditions":"Ocular Hypertension, Open-Angle Glaucoma","enrollment":30},{"nctId":"NCT01896180","phase":"PHASE2","title":"Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost","status":"COMPLETED","sponsor":"Alleanza Pharmaceuticals, Inc.","startDate":"2013-07","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension, Elevated Intraocular Pressure","enrollment":63}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":154,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"latanoprost 0.005% (drug)","genericName":"latanoprost 0.005% (drug)","companyName":"University Hospital, Basel, Switzerland","companyId":"university-hospital-basel-switzerland","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Latanoprost is a prostaglandin F (FP) receptor agonist that increases uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}